Search
Close this search box.

Outcomes and prognosis of haploidentical haematopoietic stem cell transplantation in children with FLT3-ITD mutated acute myeloid leukaemia – Bone Marrow Transplantation

  • Dohner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345–77.

    Article 
    PubMed 

    Google Scholar
     

  • Grimwade D, Ivey A, Huntly BJ. Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance. Blood. 2016;127:29–41.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Tarlock K, Sulis ML, Chewning JH, Pollard JA, Cooper T, Gamis A, et al. Hematopoietic Cell Transplantation in the Treatment of Pediatric Acute Myelogenous Leukemia and Myelodysplastic Syndromes: Guidelines from the American Society of Transplantation and Cellular Therapy. Transpl Cell Ther. 2022;28:530–45.

    Article 
    CAS 

    Google Scholar
     

  • Schlenk RF, Dohner K, Krauter J, Frohling S, Corbacioglu A, Bullinger L, et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med. 2008;358:1909–18.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, et al. Genomic Classification and Prognosis in Acute Myeloid Leukemia. N Engl J Med. 2016;374:2209–21.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Pratcorona M, Brunet S, Nomdedeu J, Ribera JM, Tormo M, Duarte R, et al. Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy. Blood. 2013;121:2734–8.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Santos FPS, Jones D, Qiao W, Cortes JE, Ravandi F, Estey EE, et al. Prognostic Value of FLT3 Mutations Among Different Cytogenetic Subgroups in Acute Myeloid Leukemia. Cancer-Am Cancer Soc. 2011;117:2145–55.

    CAS 

    Google Scholar
     

  • Egan G, Chopra Y, Mourad S, Chiang KY, Hitzler J. Treatment of acute myeloid leukemia in children: A practical perspective. Pediatr Blood Cancer. 2021;68:e28979.

    Article 
    PubMed 

    Google Scholar
     

  • Staffas A, Kanduri M, Hovland R, Rosenquist R, Ommen HB, Abrahamsson J, et al. Presence of FLT3-ITD and high BAALC expression are independent prognostic markers in childhood acute myeloid leukemia. Blood. 2011;118:5905–13.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Manara E, Basso G, Zampini M, Buldini B, Tregnago C, Rondelli R, et al. Characterization of children with FLT3-ITD acute myeloid leukemia: a report from the AIEOP AML-2002 study group. Leukemia. 2017;31:18–25.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Chang YJ, Wang Y, Liu YR, Xu LP, Zhang XH, Chen H, et al. Haploidentical allograft is superior to matched sibling donor allograft in eradicating pre-transplantation minimal residual disease of AML patients as determined by multiparameter flow cytometry: a retrospective and prospective analysis. J Hematol Oncol. 2017;10:134.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Zheng FM, Zhang X, Li CF, Cheng YF, Gao L, He YL, et al. Haploidentical- versus identical-sibling transplant for high-risk pediatric AML: A multi-center study. Cancer Commun. 2020;40:93–104.

    Article 

    Google Scholar
     

  • Stem Cell Application Group CSoHCMA. [Chinese consensus of allogeneic hematopoietic stem cell transplantation for hematological disease (III) -acute graft-versus-host disease (2020)]. Zhonghua Xue Ye Xue Za Zhi. 2020;41:529–36.

  • Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995;15:825–8.

    CAS 
    PubMed 

    Google Scholar
     

  • Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. Biol Blood Marrow Transpl. 2015;21:389–401 e1.

    Article 

    Google Scholar
     

  • Hematopoietic Stem Cell Application Group CSoHCMA, China Association for the Prevention of Hematology D. [Chinese consensus on the diagnosis and management of chronic graft-versus-host disease (2021)]. Zhonghua Xue Ye Xue Za Zhi. 2021;42:265–75.

  • Zhao X, Wang Z, Ruan G, Liu Y, Wang Y, Zhang X, et al. Impact of pre-transplantation minimal residual disease determined by multiparameter flow cytometry on the outcome of AML patients with FLT3-ITD after allogeneic stem cell transplantation. Ann Hematol. 2018;97:967–75.

    Article 
    PubMed 

    Google Scholar
     

  • Hu GH, Cheng YF, Lu AD, Wang Y, Zuo YX, Yan CH, et al. Allogeneic hematopoietic stem cell transplantation can improve the prognosis of high-risk pediatric t(8;21) acute myeloid leukemia in first remission based on MRD-guided treatment. BMC Cancer. 2020;20:553.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Stem Cell Application Group CSoHCMA, Chinese Pediatric Society CMA. [Chinese expert consensus of the allogeneic hematopoietic stem cell transplantation for pediatric acute myeloid leukemia (not APL) (2022)]. Zhonghua Xue Ye Xue Za Zhi. 2022;43:802–9.

  • Lai YR, Chen YH, Hu DM, Jiang M, Liu QF, Liu L, et al. Multicenter phase II study of a combination of cyclosporine a, methotrexate and mycophenolate mofetil for GVHD prophylaxis: results of the Chinese Bone Marrow Transplant Cooperative Group (CBMTCG). J Hematol Oncol. 2014;7:59.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Huang XJ, Liu DH, Liu KY, Xu LP, Chen H, Han W, et al. Haploidentical hematopoietic stem cell transplantation without. T-cell Deplet Treat hematological malignancies Bone Marrow Transpl. 2006;38:291–7.


    Google Scholar
     

  • Chang YJ, Xu LP, Wang Y, Zhang XH, Chen H, Chen YH, et al. Effects of Low-Dose Glucocorticoid Prophylaxis on Chronic Graft-versus-Host Disease and Graft-versus-Host Disease-Free, Relapse-Free Survival after Haploidentical Transplantation: Long-Term Follow-Up of a Controlled, Randomized Open-Label Trial. Biol Blood Marrow Transpl. 2019;25:529–37.

    Article 
    CAS 

    Google Scholar
     

  • Oran B, Cortes J, Beitinjaneh A, Chen HC, de Lima M, Patel K, et al. Allogeneic Transplantation in First Remission Improves Outcomes Irrespective of FLT3-ITD Allelic Ratio in FLT3-ITD-Positive Acute Myelogenous Leukemia. Biol Blood Marrow Transpl. 2016;22:1218–26.

    Article 
    CAS 

    Google Scholar
     

  • How J, Sykes J, Gupta V, Yee KW, Schimmer AD, Schuh AC, et al. Influence of FLT3-internal tandem duplication allele burden and white blood cell count on the outcome in patients with intermediate-risk karyotype acute myeloid leukemia. Cancer-Am Cancer Soc. 2012;118:6110–7.

    CAS 

    Google Scholar
     

  • Ahn JS, Kim HJ, Kim YK, Jung SH, Yang DH, Lee JJ, et al. Transplant outcomes of the triple-negative NPM1/FLT3-ITD/CEBPA mutation subgroup are equivalent to those of the favourable ELN risk group, but significantly better than the intermediate-I risk group after allogeneic transplant in normal-karyotype AML. Ann Hematol. 2016;95:625–35.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Brunet S, Martino R, Sierra J. Hematopoietic transplantation for acute myeloid leukemia with internal tandem duplication of FLT3 gene (FLT3/ITD). Curr Opin Oncol. 2013;25:195–204.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Deol A, Sengsayadeth S, Ahn KW, Wang HL, Aljurf M, Antin JH, et al. Does FLT3 mutation impact survival after hematopoietic stem cell transplantation for acute myeloid leukemia? A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis. Cancer-Am Cancer Soc. 2016;122:3005–14.

    CAS 

    Google Scholar
     

  • Schmid C, Labopin M, Socie G, Daguindau E, Volin L, Huynh A, et al. Outcome of patients with distinct molecular genotypes and cytogenetically normal AML after allogeneic transplantation. Blood. 2015;126:2062–9.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Meshinchi S, Alonzo TA, Stirewalt DL, Zwaan M, Zimmerman M, Reinhardt D, et al. Clinical implications of FLT3 mutations in pediatric AML. Blood. 2006;108:3654–61.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Canaani J, Labopin M, Huang XJ, Arcese W, Ciceri F, Blaise D, et al. T-cell replete haploidentical stem cell transplantation attenuates the prognostic impact of FLT3-ITD in acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Am J Hematol. 2018;93:736–44.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Helbig G, Koclega A, Wieczorkiewicz-Kabut A, Wozniczka K, Kopinska A, Boral K, et al. Pre-transplant FLT3/ITD status predicts outcome in FLT3-mutated acute myeloid leukemia following allogeneic stem cell transplantation. Ann Hematol. 2020;99:1845–53.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Buckley SA, Wood BL, Othus M, Hourigan CS, Ustun C, Linden MA, et al. Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis. Haematologica. 2017;102:865–73.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Al Hamed R, Labopin M, Daguindau E, Niittyvuopio R, Huynh A, Socie G, et al. Measurable residual disease, FLT3-ITD mutation, and disease status have independent prognostic influence on outcome of allogeneic stem cell transplantation in NPM1-mutated acute myeloid leukemia. Cancer Med. 2022;11:1068–80.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Schweitzer J, Zimmermann M, Rasche M, von Neuhoff C, Creutzig U, Dworzak M, et al. Improved outcome of pediatric patients with acute megakaryoblastic leukemia in the AML-BFM 04 trial. Ann Hematol. 2015;94:1327–36.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Stone RM, Mandrekar SJ, Sanford BL, Laumann K, Geyer S, Bloomfield CD, et al. Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation. N Engl J Med. 2017;377:454–64.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res. 2003;9:327–37.

    CAS 
    PubMed 

    Google Scholar
     

  • Burchert A, Bug G, Fritz LV, Finke J, Stelljes M, Rollig C, et al. Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3-Internal Tandem Duplication Mutation (SORMAIN). J Clin Oncol. 2020;38:2993–3002.

    Article 
    PubMed 

    Google Scholar
     

  • Xuan L, Wang Y, Huang F, Fan ZP, Xu YJ, Sun J, et al. Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial. Lancet Oncol. 2020;21:1201–12.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Shang QH, Bi L, Cheng YF, Suo P, Hu GH, Huang XJ, et al. data. figshare. Dataset. 2024. https://doi.org/10.6084/m9.figshare.24417739.